Innovations in Advanced Drug Delivery Systems: Overcoming Challenges for Personalized Medicine

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: 30 November 2025 | Viewed by 934

Special Issue Editor


E-Mail Website
Guest Editor
Center for Exact Sciences and Technology—Chemistry Course, Vale do Acaraú University, Sobral, CE, Brazil
Interests: chalcones; natural products; antimicrobial activity; zebrafish; anxiolytic activity; spectroscopy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The pursuit of more effective therapies is constantly reshaping medicine. Traditional drug administration often suffers from poor bioavailability, systemic toxicity, and a lack of targeted delivery. Advanced drug delivery systems (ADDSs) offer a promising solution, but realizing their potential faces significant obstacles. Biological barriers pose a major challenge, requiring ADDS carriers like nanoparticles to navigate the bloodstream, evade the immune system, and cross cellular membranes. This necessitates precise engineering to optimize size, shape, surface charge, and targeting ligands for enhanced circulation, reduced off-target effects, and improved cellular uptake. Scalability is another hurdle, as laboratory-developed systems often prove difficult and costly to mass-produce consistently. Reproducibility, stability, long-term storage, and stringent regulatory requirements further complicate the manufacturing of ADDSs. Despite these challenges, ADDSs hold immense potential for personalized medicine.

We look forward to receiving your contributions.

Dr. Hélcio Silva Dos Santos
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug administration
  • polymers
  • structural characterization
  • nanoparticles
  • in silico studies
  • toxicity
  • bioavailability

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

21 pages, 4846 KB  
Article
Bioactive Chalcone-Loaded Mesoporous Silica KIT-6 Nanocarrier: A Promising Strategy for Inflammation and Pain Management in Zebrafish
by Maria Kueirislene Amâncio Ferreira, Francisco Rogenio Silva Mendes, Emmanuel Silva Marinho, Roberto Lima de Albuquerque, Jesyka Macedo Guedes, Izabell Maria Martins Teixeira, Ramon Róseo Paula Pessoa Bezerra de Menezes, Vinicius Patricio Santos Caldeira, Anne Gabriella Dias Santos, Marisa Jádna Silva Frederico, Antônio César Honorato Barreto, Inês Domingues, Tigressa Helena Soares Rodrigues, Jane Eire Silva Alencar de Menezes and Hélcio Silva dos Santos
Pharmaceutics 2025, 17(8), 981; https://doi.org/10.3390/pharmaceutics17080981 - 30 Jul 2025
Viewed by 799
Abstract
Background/Objectives: The incorporation of bioactive molecules into mesoporous carriers is a promising strategy to improve stability, solubility, and therapeutic efficacy. In this study, we report for the first time the encapsulation of the synthetic chalcone 4-Cl into KIT-6 mesoporous silica and evaluate [...] Read more.
Background/Objectives: The incorporation of bioactive molecules into mesoporous carriers is a promising strategy to improve stability, solubility, and therapeutic efficacy. In this study, we report for the first time the encapsulation of the synthetic chalcone 4-Cl into KIT-6 mesoporous silica and evaluate its cytotoxicity, toxicological profile, and pharmacological activities (antinociceptive, anti-inflammatory, and anxiolytic) using an in vivo zebrafish (Danio rerio) model. Methods: Zebrafish were orally dosed with 4-Cl, 4-Cl/KIT-6, or KIT-6 (4, 20, 40 mg/kg) and mortality was recorded for 96 h. For analgesia, zebrafish pretreated with 4-Cl, 4-Cl/KIT-6, KIT-6, or morphine received a tail stimulus (0.1% formalin). Locomotor activity (quadrant crossings) was monitored for 30 min to assess analgesia (neurogenic: 0–5 min; inflammatory: 15–30 min). For inflammation, abdominal edema and weight gain were assessed 4 h after intraperitoneal carrageenan (1.5%). Zebrafish (n = 6/group) received 4-Cl, 4-Cl/KIT-6, or KIT-6 (4, 20, 40 mg/kg, p.o.). Controls received ibuprofen (100 mg/kg, p.o.) or 3% DMSO. Weight was measured hourly for 4 h post-carrageenan (difference between baseline and hourly weights). Results: Physicochemical characterizations confirmed successful encapsulation without compromising the ordered structure of KIT-6, as evidenced by a significant reduction in surface area and pore volume, indicating efficient drug incorporation. In vivo assays demonstrated that the 4-Cl/KIT-6 formulation maintained the pharmacological activities of the free chalcone, reduced toxicity, and, notably, revealed a significant anxiolytic effect for the first time. Conclusions: These findings highlight KIT-6 as a promising platform for chalcone delivery systems and provide a solid basis for future preclinical investigations. Full article
Show Figures

Figure 1

Back to TopTop